Recce Pharmaceuticals (#ASX: $RCE) is pioneering a New Class of Synthetic Anti-Infectives to combat #antibioticresistant #superbugs
Australia
Joined April 2017
- Tweets2.1K
- Following1.1K
- Followers1.7K
- Likes2.4K
Pinned Tweet
We're fighting antibiotic-resistant #superbugs with our innovative synthetic anti-infectives! 💊 🔬✨ #Innovation #AntibioticResistance #UTI #DFI
Recce Pharmaceuticals Ltd retweeted
Recce Pharmaceuticals – R327G progressing towards commercialisation
Exclusive Arrotex deal for R327G in AU/NZ DFIs. Blinded Phase III Indonesia data encouraging; unblinded soon. Valuation A$2.15/sh.
📖 Full analysis: edisongroup.com/research/r32…
$RCE @ReccePharma
Recce Pharmaceuticals Ltd retweeted
$RCE Recce Pharmaceuticals Managing Director and CEO James Graham discusses Arrotex's R327G commercialisation rights in Australia and New Zealand and the regulatory steps required before a TGA application.
Watch the interview.
@ReccePharma
#ASX #RCE #Biotech
Recce Pharmaceuticals Ltd retweeted
We spoke with James Graham, Managing Director & CEO of $RCE Recce Pharmaceuticals, at Ignite Summit about RECCE® 327, Phase 3 trials and upcoming clinical milestones.
@ReccePharma
#ASX #SmallCaps #Biotech #IgniteSummit
Recce Pharmaceuticals Ltd retweeted
$RCE Recce Pharma R327G Phase 3 data heads to DMC review - ICYMI tinyurl.com/2c7t34um @ReccePharma #RCE #RECEF #ASX #ASXNews
Recce Pharmaceuticals Ltd retweeted
$RCE @ReccePharma has signed an exclusive licensing and commercialisation agreement with Arrotex Pharmaceuticals for its RECCE 327 (R327G) topical gel to treat diabetic foot infections (DFIs) in Australia and New Zealand.
Read it here: buff.ly/FKt15gr
Recce Pharmaceuticals Ltd retweeted
$RCE Recce Pharmaceuticals signs Arrotex deal for RECCE 327 in Australia and New Zealand tinyurl.com/24mabzrf @ReccePharma #RCE #RECEF #ASX #ASXNews
Recce Pharmaceuticals Ltd (ASX: RCE; FSE: R9Q) and Arrotex Pharmaceuticals Pty Ltd., today announced an exclusive license and commercialization agreement for Arrotex to register and commercialize RECCE® 327 topical gel (R327G) for the treatment of diabetic foot infections (DFIs) in Australia and New Zealand.
Read the full ann here: recce.com.au/company-announc…
Recce Pharmaceuticals Ltd retweeted
A review of blinded data from Recce’s Phase III trial of its RECCE 327 Gel in diabetic foot infections has indicated strong efficacy.
#ASX #health @ReccePharma $RCE
stockhead.com.au/health/recc…
Recce Pharmaceuticals Ltd retweeted
$RCE Recce Pharmaceuticals advances Phase 3 diabetic foot infection trial to independent data review tinyurl.com/28252q7p @ReccePharma #RCE #RECEF #ASX #ASXNews
Recce Pharmaceuticals Ltd retweeted
$RCE Recce Pharmaceuticals has submitted data from 75 patients for independent DMC review of its Phase 3 diabetic foot infection trial, following encouraging blinded clinical outcomes and a positive safety profile.
@ReccePharma
#ASX #RCE #Biotech
#ASX Announcement - Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), advises that a review of blinded data of its current Phase III trial undertaken by clinical experts and a statistician indicates strong efficacy along with a very positive safety profile.
Read the full ann: recce.com.au/company-announc…
Recce Pharmaceuticals (ASX: RCE) CEO James Graham will be presenting at the MST Biotech & Healthcare Webinar – The Infection Playbook.
Join James alongside Dr David Foster (Island Pharmaceuticals), Doug Ward (Lumos Diagnostics) and Brent Barnes (Clever Culture Systems) as they discuss innovation across key areas of healthcare and biotechnology.
Tuesday, 20 October 2026
11:00 AM AEDT
Register here: mstfinancial-au.zoom.us/webi…
Bringing new antibacterial technologies to market requires more than scientific innovation.
disAMR explores the pathway from clinical development to commercialisation.
Read more: disamr.com/articles/building…
#AMR #Biotechnology
ONE WEEK TO GO!
Recce Pharmaceuticals (ASX: RCE) is heading to Hong Kong Ignite Summit 2026!
CEO James Graham will present Recce’s latest clinical developments and progress in advancing a new class of synthetic anti-infectives.
Event: 14–15 October 2026
RCE Company Presentation: 14 October | 2:40 PM (HKT)
Venue: Grand Hyatt Hong Kong, Wan Chai
We look forward to connecting with investors and industry professionals!
Recce Pharmaceuticals Ltd retweeted
$RCE Recce Pharmaceuticals advances R327 as diabetes and antibiotic resistance burdens converge tinyurl.com/2dl5nsvz @ReccePharma #RCE #RECEF #ASX #ASXNews
Recce Pharmaceuticals’ 2026 Annual Report is now available. Discover our progress over the past year, key milestones achieved, and what lies ahead.
recce.com.au/company-announc…
Recce Pharmaceuticals Ltd retweeted
$RCE Recce Pharmaceuticals Managing Director and CEO James Graham outlines the next milestones as patient recruitment, dosing and Phase 3 trial activities continue.
@ReccePharma
#ASX #RCE #Biotechnology
Recce Pharmaceuticals Ltd retweeted
$RCE Recce Pharmaceuticals Managing Director and CEO James Graham discusses HREC approval of the amended Phase 3 DFI trial design and R327G’s clinical development pathway.
@ReccePharma
#ASX #RCE #Biotechnology
Recce Pharmaceuticals Ltd retweeted
The amendment adds a randomised, active-controlled, non-inferiority study in DFI, enrolling a total of 208 participants randomised between R327G and a physician-selected antibiotic.
@ReccePharma #ASX #health
stockhead.com.au/resources/r…
Recce Pharmaceuticals Ltd retweeted
$RCE Recce Pharmaceuticals secures HREC approval for expanded Phase 3 diabetic foot infection trial tinyurl.com/266pwpnm @ReccePharma #RCE #RECEF #ASX #ASXNews